A Phase II Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of BNC210 in Hospitalised Elderly Patients With Agitation
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2019
Price : $35 *
At a glance
- Drugs BNC 210 (Primary)
- Indications Agitation
- Focus Therapeutic Use
- Sponsors Bionomics
- 30 May 2019 Status changed from recruiting to completed.
- 02 Oct 2018 According to a Bionomics media release, data readout is expected Q1, 2019.
- 02 Jun 2018 New trial record